The U.S. Food and Drug Administration’s (or FDA) approval for Keytruda on October 2, 2015, to treat patients suffering with advanced non-small cell lung cancer (or NSCLC) is considered to be a major ...

The biotech will explore the potential of BI-1808 plus Keytruda in clear cell and high-grade serous ovarian cancer subtypes.

Merck (NYSE:MRK) is preparing to launch a subcutaneously delivered formulation of their blockbuster cancer medication Keytruda for patient convenience as the company approaches a steep patent cliff ...

Merck MRK announced that the FDA has accepted its regulatory filing seeking approval for the subcutaneous (under the skin or SC) formulation of the blockbuster drug Keytruda (pembrolizumab). This ...